Literature DB >> 35412592

Strategies to Identify and Recruit Women at High Risk for Breast Cancer to a Randomized Controlled Trial of Web-based Decision Support Tools.

Julia E McGuinness1,2, Gauri Bhatkhande3, Jacquelyn Amenta1,2, Thomas Silverman4, Jennie Mata1,2, Ashlee Guzman1,2, Ting He5, Jill Dimond6, Tarsha Jones7, Rita Kukafka2,4,8, Katherine D Crew1,2,3.   

Abstract

We evaluated strategies to identify and recruit a racially/ethnically diverse cohort of women at high-risk for breast cancer to a randomized controlled trial (RCT). We enrolled 300 high-risk women and 50 healthcare providers to a RCT of standard educational materials alone or in combination with web-based decision support tools. We implemented five strategies to identify high-risk women: (i) recruitment among patients previously enrolled in a study evaluating breast cancer risk; (ii) automated breast cancer risk calculation using information extracted from the electronic health record (EHR); (iii) identification of women with atypical hyperplasia or lobular carcinoma in situ (LCIS) using International Classification of Diseases (ICD)-9/10 diagnostic codes; (iv) clinical encounters with enrolled healthcare providers; (v) recruitment flyers/online resources. Breast cancer risk was calculated using either the Gail or Breast Cancer Surveillance Consortium (BCSC) models. We identified 6,229 high-risk women and contacted 3,459 (56%), of whom 17.2% were identified from prior study cohort, 37.5% through EHR risk information, 14.8% with atypical hyperplasia/LCIS, 29.0% by clinical encounters, and 1.5% through recruitment flyers. Women from the different recruitment sources varied by age and 5-year invasive breast cancer risk. Of 300 enrolled high-risk women, 44.7% came from clinical encounters and 27.3% from prior study cohort. Comparing enrolled with not-enrolled participants, there were significant differences in mean age (57.2 vs. 59.1 years), proportion of non-Whites (41.5% vs. 54.8%), and mean 5-year breast cancer risk (3.0% vs. 2.3%). We identified and successfully recruited diverse high-risk women from multiple sources. These strategies may be implemented in future breast cancer chemoprevention trials. PREVENTION RELEVANCE: We describe five strategies to identify and successfully recruit a large cohort of racially/ethnically diverse high-risk women from multiple sources to a randomized controlled trial evaluating interventions to increase chemoprevention uptake. Findings could inform recruitment efforts for future breast cancer prevention trials to increase recruitment yield of high-risk women. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2022        PMID: 35412592      PMCID: PMC9167698          DOI: 10.1158/1940-6207.CAPR-21-0593

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  30 in total

1.  Exemestane for breast-cancer prevention in postmenopausal women.

Authors:  Paul E Goss; James N Ingle; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Jean Wactawski-Wende; Anne McTiernan; John Robbins; Karen C Johnson; Lisa W Martin; Eric Winquist; Gloria E Sarto; Judy E Garber; Carol J Fabian; Pascal Pujol; Elizabeth Maunsell; Patricia Farmer; Karen A Gelmon; Dongsheng Tu; Harriet Richardson
Journal:  N Engl J Med       Date:  2011-06-04       Impact factor: 91.245

2.  Usability Testing of a Web-Based Decision Aid for Breast Cancer Risk Assessment Among Multi-Ethnic Women.

Authors:  Austin M Coe; William Ueng; Jennifer M Vargas; Raven David; Alejandro Vanegas; Katherine Infante; Meghna Trivedi; Haeseung Yi; Jill Dimond; Katherine D Crew; Rita Kukafka
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10

3.  Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.

Authors:  Kala Visvanathan; Carol J Fabian; Elissa Bantug; Abenaa M Brewster; Nancy E Davidson; Andrea DeCensi; Justin D Floyd; Judy E Garber; Erin W Hofstatter; Seema A Khan; Maria C Katapodi; Sandhya Pruthi; Rachal Raab; Carolyn D Runowicz; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2019-09-03       Impact factor: 44.544

4.  Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

Authors:  D Craig Allred; Stewart J Anderson; Soonmyung Paik; D Lawrence Wickerham; Iris D Nagtegaal; Sandra M Swain; Elefetherios P Mamounas; Thomas B Julian; Charles E Geyer; Joseph P Costantino; Stephanie R Land; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

5.  Factors affecting breast cancer risk reduction practices among California physicians.

Authors:  Celia Patricia Kaplan; Jennifer S Haas; Eliseo J Pérez-Stable; Genevieve Des Jarlais; Steven E Gregorich
Journal:  Prev Med       Date:  2004-12-10       Impact factor: 4.018

6.  National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities.

Authors:  Worta McCaskill-Stevens; John W Wilson; Elise D Cook; Cora L Edwards; Regina V Gibson; Diane L McElwain; Colmar D Figueroa-Moseley; Electra D Paskett; Noma L Roberson; D Lawrence Wickerham; Norman Wolmark
Journal:  Clin Trials       Date:  2013-01-18       Impact factor: 2.486

7.  Stratification of breast cancer risk in women with atypia: a Mayo cohort study.

Authors:  Amy C Degnim; Daniel W Visscher; Hal K Berman; Marlene H Frost; Thomas A Sellers; Robert A Vierkant; Shaun D Maloney; V Shane Pankratz; Piet C de Groen; Wilma L Lingle; Karthik Ghosh; Lois Penheiter; Thea Tlsty; L Joseph Melton; Carol A Reynolds; Lynn C Hartmann
Journal:  J Clin Oncol       Date:  2007-06-11       Impact factor: 44.544

8.  Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

Authors:  Jack Cuzick; Ivana Sestak; John F Forbes; Mitch Dowsett; Jill Knox; Simon Cawthorn; Christobel Saunders; Nicola Roche; Robert E Mansel; Gunter von Minckwitz; Bernardo Bonanni; Tiina Palva; Anthony Howell
Journal:  Lancet       Date:  2013-12-12       Impact factor: 79.321

9.  Pilot study of decision support tools on breast cancer chemoprevention for high-risk women and healthcare providers in the primary care setting.

Authors:  Rita Kukafka; Jiaqi Fang; Alejandro Vanegas; Thomas Silverman; Katherine D Crew
Journal:  BMC Med Inform Decis Mak       Date:  2018-12-17       Impact factor: 2.796

Review 10.  Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.

Authors:  S G Smith; I Sestak; A Forster; A Partridge; L Side; M S Wolf; R Horne; J Wardle; J Cuzick
Journal:  Ann Oncol       Date:  2015-12-08       Impact factor: 32.976

View more
  1 in total

1.  Patient and Provider Web-Based Decision Support for Breast Cancer Chemoprevention: A Randomized Controlled Trial.

Authors:  Katherine D Crew; Gauri Bhatkhande; Thomas Silverman; Jacquelyn Amenta; Tarsha Jones; Julia E McGuinness; Jennie Mata; Ashlee Guzman; Ting He; Jill Dimond; Wei-Yann Tsai; Rita Kukafka
Journal:  Cancer Prev Res (Phila)       Date:  2022-10-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.